INMB INmune Bio, Inc.
Healthcare$1.43-1.38%ClosedMarket Cap: $38.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.96
P/S
0.00
EV/EBITDA
-0.70
DCF Value
$0.76
FCF Yield
-53.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-170.9%
ROA
-161.1%
ROIC
-204.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-5.8M | $-5.4M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-5.5M | $-5.3M | $— | — |
| FY null | $50.0K | 100.0% | $-30.9M | $-45.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.4M | $-6.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-24.6M | $-24.5M | $— | — |
| Q1 null | $50.0K | 100.0% | $-9.9M | $-9.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-9.5M | $-9.2M | $— | — |
| FY null | $14.0K | 100.0% | $-42.6M | $-42.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.3M | $-12.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-9.9M | $-9.7M | $— | — |
| Q1 null | $14.0K | 100.0% | $-11.0M | $-11.0M | $— | — |
| Q4 2023 | $28.0K | 100.0% | $-8.4M | $-8.4M | $-0.47 | — |